UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

Thrombosis and haemostasis, 2011-06, Vol.105 (6), p.1080-1090

2011

Volltextzugriff (PDF)

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

Thrombosis and haemostasis, 2010-09, Vol.104 (3), p.633-641

2010

Volltextzugriff (PDF)

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Thrombosis and haemostasis, 2012-05, Vol.107 (5), p.925-934

2012

Volltextzugriff (PDF)

Population PK analysis of DX-9065A in patients with acute coronary syndrome

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P89-P89

2005

Volltextzugriff (PDF)

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot

Journal of thrombosis and haemostasis, 2004-02, Vol.2 (2), p.234-241

2004

Volltextzugriff (PDF)

Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases

European journal of medicinal chemistry, 1995, Vol.30 (5), p.387-394

1995

Volltextzugriff (PDF)

Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)

BMJ open, 2015-12, Vol.5 (12), p.e009562-e009562

2015

Volltextzugriff (PDF)

FXa inhibitor

Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2000-04, Vol.45 (6 Suppl), p.1169

Kunitada, S

2000

Volltextzugriff (PDF)

Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants

Thrombosis and haemostasis, 1997-11, Vol.78 (5), p.1366

1997

Volltextzugriff (PDF)

A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction

The Journal of pharmacology and experimental therapeutics, 1991-04, Vol.257 (1), p.487

1991

Volltextzugriff (PDF)

First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation

Circulation (New York, N.Y.), 2002-05, Vol.105 (20), p.2385-2391

2002

Volltextzugriff (PDF)

Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin

Thrombosis and haemostasis, 2002-11, Vol.88 (5), p.733-738

2002

Volltextzugriff (PDF)

Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue

Circulation (New York, N.Y.), 1992-02, Vol.85 (2), p.526-532

1992

Volltextzugriff (PDF)

Design, synthesis and biological activities of orally active coagulation factor Xa inhibitors

European journal of medicinal chemistry, 1995, Vol.30, p.139s-143s

1995

Volltextzugriff (PDF)

Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers

Clinical pharmacology and therapeutics, 1999-09, Vol.66 (3), p.258-264

1999

Volltextzugriff (PDF)

Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat

Shock (Augusta, Ga.), 2002-02, Vol.17 (2), p.159-162

2002

Volltextzugriff (PDF)

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

Thrombosis research, 1995-10, Vol.80 (1), p.99-104

1995

Volltextzugriff (PDF)

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist

Thrombosis and haemostasis, 2004-12, Vol.92 (6), p.1229-1231

2004

Volltextzugriff (PDF)

Factor Xa Inhibitors

Current pharmaceutical design, 1996-10, Vol.2 (5), p.531-542

1996

Volltextzugriff (PDF)

A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats

Thrombosis research, 2000-04, Vol.98 (2), p.175-185

2000

Volltextzugriff (PDF)

Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction

Blood, 1992-03, Vol.79 (6), p.1420-1427

1992

Volltextzugriff (PDF)

DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model

Thrombosis and haemostasis, 1999-05, Vol.81 (5), p.828-34

1999

Volltextzugriff (PDF)

Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates

Circulation (New York, N.Y.), 1995-08, Vol.92 (3), p.485-491

1995

Volltextzugriff (PDF)

A Specific Inhibitor of Factor Xa, DX-9065a, Exerts Effective Protection against Experimental Tumor-Induced Disseminated Intravascular Coagulation in Rats

Thrombosis research, 1999-10, Vol.96 (2), p.135-143

1999

Volltextzugriff (PDF)

Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor

Journal of thrombosis and thrombolysis, 2004-12, Vol.18 (3), p.193-197

2004

Volltextzugriff (PDF)

1 – 25 von 605

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(475)
Mit Volltextzugriff
(531)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(362)
Life Sciences & Biomedicine
(325)
Humans
(282)
Biological And Medical Sciences
(152)
Hepatitis C Virus
(135)
Virology
(117)
Animals
(111)
Biochemistry & Molecular Biology
(104)
Molecular Sequence Data
(95)
Fundamental And Applied Biological Sciences. Psychology
(89)
Base Sequence
(88)
Cell Line
(87)
Hepacivirus - Genetics
(87)
Medical Sciences
(73)
Aids/hiv
(65)
Amino Acid Sequence
(64)
Microbiology
(63)
Male
(60)
Female
(53)
Hepacivirus - Physiology
(52)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Population PK analysis of DX-9065A in patients with acute coronary syndrome

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot

Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases

Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)

FXa inhibitor

Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants

A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction

First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation

Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin

Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue

Design, synthesis and biological activities of orally active coagulation factor Xa inhibitors

Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers

Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist

Factor Xa Inhibitors

A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats

Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction

DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model

Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates

A Specific Inhibitor of Factor Xa, DX-9065a, Exerts Effective Protection against Experimental Tumor-Induced Disseminated Intravascular Coagulation in Rats

Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor

Suchergebnisse filtern